Overview

A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

Status:
Active, not recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to examine the side effects that participants with metastatic breast cancer experience when taking abemaciclib with or without food.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company